MUNICH, Germany, Sept. 29 Nomad-Bio-New-Company
MUNICH, Germany, Sept. 29 /PRNewswire/ -- NOMAD Bioscience GmbH, Munich,
Germany (NOMAD) is a private biotechnology company developing plant-made
biomaterials and biopharmaceuticals that address critical unmet needs. NOMAD
is developing a series of high-value products such as nanopatterned materials,
protein scaffolds and templates, proteins and enzymes for important markets
including biofuels, electric batteries, and biopharmaceuticals.
Nomad's plant-based protein expression technologies are being licensed
from several companies for a broad range of products. NOMAD's proprietary
technologies further improve the upstream part of the manufacturing process,
but most importantly, they provide for novel downstream solutions that
together with the in-licensed upstream components should result in a superior
fully integrated manufacturing process for most of NOMAD's intended products.
Another major focus of NOMAD is innovations that provide for full integration
of the novel process components and novel product parts into existing
industrial processes/products.
NOMAD's biomaterial pipeline consists of several selected product
candidates, including plant-made cellulase enzymes (expected impact: up to 30%
lower manufacturing cost of bioethanol), nanostructured polyadsorbents for
affinity purification of biopharmaceuticals (low cost polyaffinity
nanoparticles that replace expensive current affinity resins) and
nanopatterned electrodes (batteries with improved electrochemical cycling
properties and electrode capacity).
NOMAD's pharmaceutical portfolio is focused on three 'biosimilar' versions
of the proteins currently constituting a $15 B market: Insulin, Etanercept
(Enbrel(R)), and Trastuzumab (Herceptin(R)). Our lead pharmaceutical product,
Insulin, targets the US$7.5 billion Insulin market. NOMAD's Insulin will
provide an economical alternative to commercially available Insulin to better
serve developing nations and meet the anticipated surge in demand. The
biologics segment of the portfolio offers the longer term higher upside
margins associated with pharmaceuticals while controlling the development risk
through selection of early candidates from among 'biosimilar' products.
NOMAD intends to develop and commercialize its products in partnership
with leading industry companies. The Company is focusing on rapidly expanding
markets with ability and willingness to adopt new generation processes for new
as well as existing products, in return for lower manufacturing costs, better
ecological profiles and innovative value capture mechanisms. NOMAD's value is
tied to technology platforms that reduce capital and running costs of the
plant-based production to new lows, diversified portfolio of carefully chosen
and innovative candidates that address attractive markets, very fast R&D
engine and very short production cycle.
The founder of NOMAD is Prof. Dr. Yuri Gleba. Prior to founding NOMAD in
2008, Dr. Gleba co-founded two other biotech companies, Icon Genetics
(Germany, USA) and Phytomedics (USA). He has been the CEO of Icon Genetics
since its inception in 1999 and he has brought it to a successful exit in 2006
by selling the company to Bayer AG; he continues to manage it now. In addition
to being an entrepreneur, Dr. Gleba has over 30 years of experience in
successful management of academic/corporate R&D projects. He is a well
respected scientist and inventor as evidenced by his more than 200 research
papers, books and over 30 patent families and election to six national and
international academies of science. Over the next few months, NOMAD intends to
build a team of managers that have the necessary qualifications.
SOURCE NOMAD Bioscience GmbH
